Cargando…

Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials

BACKGROUND: Pre-clinical evidence shows that fixed dose rate (FDR) infusion of gemcitabine could optimize plasma concentration of gemcitabine, while the clinical efficacy and toxicity of FDR infusion of gemcitabine in advanced pancreatic carcinoma has not been systematically investigated. Thus, this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Jiqing, Yuan, Jing, Lu, Laichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251942/ https://www.ncbi.nlm.nih.gov/pubmed/25421173 http://dx.doi.org/10.1186/s13000-014-0214-8

Ejemplares similares

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma
por: Bengala, C, et al.
Publicado: (2005)

Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study
por: López-Pousa, A, et al.
Publicado: (2006)

Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2010)

Prolonged low-dose infusion for gemcitabine: a systematic review
por: Zhao, Dehua, et al.
Publicado: (2019)

Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma
por: Guan, Z, et al.
Publicado: (2003)

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer
por: Ko, A H, et al.
Publicado: (2005)

Variable versus fixed-rate infusion of phenylephrine during cesarean delivery: a randomized controlled trial
por: Hasanin, Ahmed, et al.
Publicado: (2019)

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
por: Kamata, Ken, et al.
Publicado: (2023)

Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder
por: Mohanty, N. K., et al.
Publicado: (2008)

Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
por: Liu, Xiaoyu, et al.
Publicado: (2016)

Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer
por: Dehua, Zhao, et al.
Publicado: (2018)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma
por: von Delius, Stefan, et al.
Publicado: (2005)

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer
por: Goldstein, D, et al.
Publicado: (2012)

A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)
por: Rasmussen, Louise Skau, et al.
Publicado: (2023)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
por: Heinemann, Volker, et al.
Publicado: (2008)

Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials
por: Jin, Jiamin, et al.
Publicado: (2018)

Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract
por: Hsu, C, et al.
Publicado: (2004)

Comparison of Postoperative Pain and Adverse Effects between Variable-Rate Feedback Infusion and Conventional Fixed-Rate Basal Infusion Modes of Patient-Controlled Epidural Analgesia Following Open Gastrectomy: A Randomized Controlled Trial
por: Jang, Yoo Kyung, et al.
Publicado: (2021)

Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Li, Qin, et al.
Publicado: (2014)

Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials
por: Ouyang, Guoqing, et al.
Publicado: (2021)

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
por: Chen, Justin A., et al.
Publicado: (2022)

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong, Dao-Jun, et al.
Publicado: (2013)

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
por: Eickhoff, A, et al.
Publicado: (2006)

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Li, Doudou, et al.
Publicado: (2015)

Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer
por: Winer, Arthur, et al.
Publicado: (2021)

Insulin Infusion Dosing in Pediatric Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Forestell, Ben, et al.
Publicado: (2023)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma
por: Du, Zheng, et al.
Publicado: (2022)

Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials
por: Tong, Mengting, et al.
Publicado: (2019)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
por: Hu, Jing, et al.
Publicado: (2011)

Fixed dose artesunate amodiaquine – a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine
por: Ogutu, Bernhards, et al.
Publicado: (2014)

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
por: Heinrich, Stefan, et al.
Publicado: (2011)

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
por: Friess, Helmut, et al.
Publicado: (2006)

Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction
por: Shibata, Takashi, et al.
Publicado: (2016)

S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials
por: Zhong, Sheng, et al.
Publicado: (2017)

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)
por: Di Costanzo, F, et al.
Publicado: (2005)

Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis
por: Yang, Zu-Yao, et al.
Publicado: (2013)

Efficacy and Safety of Low Dose Insulin Infusion against Standard Dose Insulin Infusion in Children with Diabetic Ketoacidosis- An Open Labelled Randomized Controlled Trial
por: Saikia, Diganta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oqs53kjmfkhdv379ckeimhcap1